167 related articles for article (PubMed ID: 25746036)
21. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
22. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
23. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of BRAF mutation and extracellular regulated protein kinases activation in nasal mucosa melanomas].
Li HY; Zhou L; Tian J; Cong N
Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3399-402. PubMed ID: 21223812
[TBL] [Abstract][Full Text] [Related]
25. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
26. Frequency of TERT Promoter Mutations in Prostate Cancer.
Stoehr R; Taubert H; Zinnall U; Giedl J; Gaisa NT; Burger M; Ruemmele P; Hurst CD; Knowles MA; Wullich B; Hartmann A
Pathobiology; 2015; 82(2):53-7. PubMed ID: 25997473
[TBL] [Abstract][Full Text] [Related]
27. TERT promoter mutations in melanoma survival.
Nagore E; Heidenreich B; Rachakonda S; Garcia-Casado Z; Requena C; Soriano V; Frank C; Traves V; Quecedo E; Sanjuan-Gimenez J; Hemminki K; Landi MT; Kumar R
Int J Cancer; 2016 Jul; 139(1):75-84. PubMed ID: 26875008
[TBL] [Abstract][Full Text] [Related]
28. [Expression of BRMS1 gene protein in nasal and paranasal sinus carcinomas].
Wang Y; Zhao Z; Chen L; Cong L; Zhang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Oct; 25(20):920-1. PubMed ID: 22239051
[TBL] [Abstract][Full Text] [Related]
29. A Case of Sinonasal Melanoma With Unusual Primary Exon 17 KIT D820G Mutation.
Pilozzi E; Bartolazzi A; Fochetti F; Duranti E; Scarpino S; Valeriani M; Moriconi P; Ruco L
Appl Immunohistochem Mol Morphol; 2016; 24(10):e94-e97. PubMed ID: 27153441
[TBL] [Abstract][Full Text] [Related]
30. Outcome of sinonasal melanoma: clinical experience and review of the literature.
Roth TN; Gengler C; Huber GF; Holzmann D
Head Neck; 2010 Oct; 32(10):1385-92. PubMed ID: 20146340
[TBL] [Abstract][Full Text] [Related]
31. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
[TBL] [Abstract][Full Text] [Related]
32. Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.
Yang S; Leone D; Frydenlund N; Hoang M; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
Melanoma Res; 2016 Aug; 26(4):361-6. PubMed ID: 27244099
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of DLEC1 in sinonasal inverted papilloma and squamous cell carcinoma.
Chang PH; Huang CC; Lee TJ; Lee YS; Tsai CN
J Otolaryngol Head Neck Surg; 2012 Apr; 41(2):94-101. PubMed ID: 22569009
[TBL] [Abstract][Full Text] [Related]
34. [Mucosal malignant melanoma of the nasal cavity and paranasal sinuses: two case reports of nonspecific clinical features].
Wang QG
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 39(4):437-9. PubMed ID: 17657278
[TBL] [Abstract][Full Text] [Related]
35. Malignant melanoma of the nasal cavity and paranasal sinuses.
Lund VJ
Ear Nose Throat J; 1993 Apr; 72(4):285-90. PubMed ID: 8486108
[No Abstract] [Full Text] [Related]
36. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
37. Malignant melanoma of nasal cavity and paranasal sinuses: report of 24 patients and literature review.
Clifton N; Harrison L; Bradley PJ; Jones NS
J Laryngol Otol; 2011 May; 125(5):479-85. PubMed ID: 21255478
[TBL] [Abstract][Full Text] [Related]
38. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage?
Regauer S; Ott A; Berghold A; Beham A
J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093
[TBL] [Abstract][Full Text] [Related]
39. Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.
Scholz SL; Thomasen H; Reis H; Möller I; Darawsha R; Müller B; Dekowski D; Sucker A; Schilling B; Schadendorf D; Steuhl KP; Paschen A; Westekemper H; Meller D; Griewank KG
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5854-61. PubMed ID: 26348634
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY
Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
